Evidence map›Paper›PMID 33197765›Full record

ReviewBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2021

SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role.

Ahmad Ud Din, Maryam Mazhar, Muhammed Waseem, Waqar Ahmad, Asma Bibi, Adil Hassan, Niaz Ali, Wang Gang, Gao Qian, Razi Ullah and 5 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 3 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 3 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010-20.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Pooled it
  4. Trial
  5. Review
  6. Article
  7. Impact of nutrition on long COVID.Sports medicine and health science · 2026
    Review
  8. Review
  9. Review
  10. Review
  11. BMJ open · 2025
    Article
  12. The role ofHeliyon · 2024
    Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Two Case Reports of Newly Diagnosed Crohn's Disease after COVID-19 in Pediatric Patients.The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 2 countries.

Ahmad Ud DinDrug Discovery Research Center, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Maryam MazharResearch Center of Integrated Traditional Chinese and Western Medicine, Affiliated Traditional Medicine Hospital, Southwest Medical University, Luzhou, China.
Muhammed WaseemState Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, College of Horticulture, South China Agricultural University, Guangzhou, 510642, China.
Waqar AhmadDrug Discovery Research Center, Southwest Medical University, Luzhou, 646000, Sichuan, China; College of Marine Life Sciences and Institute of Evolution and Marine Biodiversity, Ocean University of China, Qingdao, 266003, China.
Asma BibiInstitute of Zoonosis Anhui Medical University, Hefei Anhui, 230032, China.
Adil HassanKey Laboratory for Bio-rheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants Bioengineering College of Chongqing University, Chongqing, 400030, China.
Niaz AliState Key Laboratory for Conservation and Utilization of Subtropical Agro-bio-resources, College of Life Science and Technology, Guangxi University, 100 Daxue Road, Nanning, 530004, Guangxi, China.
Wang GangDrug Discovery Research Center, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Gao QianDrug Discovery Research Center, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Razi UllahKey Laboratory for Bio-rheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants Bioengineering College of Chongqing University, Chongqing, 400030, China.
Tariq ShahState Key Laboratory of Grassland Agro-Ecosystem, School of Life Sciences, Lanzhou University, Lanzhou, 730000, China.
Mehraj UllahDepartment of Biotechnology School of Fermentation Engineering Tianjin University of Science and Technology China, China.
Israr KhanSchool of Life Sciences, Lanzhou University, China.
Muhammad Farrukh NisarDepartment of Physiology and Biochemistry, Cholistan University of Veterinary and Animal Sciences (CUVAS), Bahawalpur, 63100, Pakistan.
Jianbo WuDrug Discovery Research Center, Southwest Medical University, Luzhou, 646000, Sichuan, China. Electronic address: jbwucn1996@yahoo.com.
Southwest Medical University · CNChongqing University of Technology · CNLanzhou University · CNAnhui Medical University · CNGuangxi University · CNSouth China Agricultural University · CNTianjin University of Science and Technology · CNUniversity of Veterinary and Animal Sciences · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In December 2019, a pneumonia outbreak of unknown etiology was reported which caused panic in Wuhan city of central China, which was later identified as Coronavirus disease (COVID-19) caused by a novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by the Chinese Centre for Disease Control and Prevention (CDC) and WHO. To date, the SARS-CoV-2 spread has already become a global pandemic with a considerable death toll. The associated symptoms of the COVID-19 infection varied with increased inflammation as an everyday pathological basis. Among various other symptoms such as fever, cough, lethargy, gastrointestinal (GI) symptoms included diarrhea and IBD with colitis, have been reported. Currently, there is no sole cure for COVID-19, and researchers are actively engaged to search out appropriate treatment and develop a vaccine for its prevention. Antiviral for controlling viral load and corticosteroid therapy for reducing inflammation seems to be inadequate to control the fatality rate. Based on the available related literature, which documented GI symptoms with diarrhea, inflammatory bowel diseases (IBD) with colitis, and increased deaths in the intensive care unit (ICU), conclude that dysbiosis occurs during SARS-COV-2 infection as the gut-lung axis cannot be ignored. As probiotics play a therapeutic role for GI, IBD, colitis, and even in viral infection. So, we assume that the inclusion of studies to investigate gut microbiome and subsequent therapies such as probiotics might help decrease the inflammatory response of viral pathogenesis and respiratory symptoms by strengthening the host immune system, amelioration of gut microbiome, and improvement of gut barrier function.

Indexed as

DysbiosisGastrointestinal MicrobiomeProbioticsCOVID-19HumansSARS-CoV-2ColitisCOVID-19Gut microbiomeIBDICUProbiotics

Identifiers

PMID33197765
PMCPMC7657099
OpenAlexW3103713425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.